MARKET

KALA

KALA

Kala Pharmaceuticals Inc
NASDAQ
0.9000
-0.0640
-6.64%
After Hours: 0.8890 -0.011 -1.22% 19:59 12/05 EST
OPEN
1.000
PREV CLOSE
0.9640
HIGH
1.020
LOW
0.8576
VOLUME
11.34M
TURNOVER
--
52 WEEK HIGH
20.60
52 WEEK LOW
0.6076
MARKET CAP
7.39M
P/E (TTM)
-0.1516
1D
5D
1M
3M
1Y
5Y
1D
KALA BIO Raises $10M in Direct Offering
TipRanks · 12h ago
KALA BIO ANNOUNCES CLOSING OF $10 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 14h ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 1d ago
KALA BIO to raise $10 mln in registered direct offering
Seeking Alpha · 1d ago
Kala Bio announces $10M registered direct offering priced at-the-market
TipRanks · 1d ago
KALA BIO Enters Announces $10M Registered Direct Offering Of 10M Shares At $1/Share To Repay Debt And Fund Corporate Purposes
Benzinga · 1d ago
KALA BIO INC - PURCHASE PRICE SET AT $1.00 PER SHARE IN DIRECT OFFERING
Reuters · 1d ago
Press Release: KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Dow Jones · 1d ago
More
About KALA
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Webull offers KALA BIO Inc stock information, including NASDAQ: KALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KALA stock methods without spending real money on the virtual paper trading platform.